Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer

Phase 1

Completed

Conditions: Prostate Cancer
Pancreatic Cancer
Bladder Cancer

Interventions: Radiation: [124I] PSCA-Minibody PET/CT imaging of the whole body

First Posted Date: 2014-03-20

Last Posted Date: 2020-07-27

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 8

Registration Number: NCT02092948

Locations: 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

Phase 1

Terminated

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: cyclophosphamide
Drug: fludarabine phosphate
Biological: NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL
Biological: dendritic cell vaccine therapy
Biological: aldesleukin
Radiation: fludeoxyglucose F 18
Procedure: positron emission tomography
Other: laboratory biomarker analysis

First Posted Date: 2014-02-25

Last Posted Date: 2019-02-28

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 4

Registration Number: NCT02070406

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor
Metastatic Cancer

Interventions: Drug: PARP inhibitor BMN-673
Drug: temozolomide
Drug: irinotecan hydrochloride
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2014-01-30

Last Posted Date: 2022-09-26

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 44

Registration Number: NCT02049593

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer

Phase 2

Completed

Conditions: Human Papilloma Virus Infection
Stage III Squamous Cell Carcinoma of the Hypopharynx
Stage III Squamous Cell Carcinoma of the Larynx
Stage III Squamous Cell Carcinoma of the Oropharynx
Stage III Verrucous Carcinoma of the Larynx
Stage IV Squamous Cell Carcinoma of the Hypopharynx
Stage IV Verrucous Carcinoma of the Larynx
Stage IVA Squamous Cell Carcinoma of the Larynx
Stage IVA Squamous Cell Carcinoma of the Oropharynx
Stage IVA Verrucous Carcinoma of the Larynx

Interventions: Drug: paclitaxel
Drug: carboplatin
Radiation: intensity-modulated radiation therapy
Procedure: quality-of-life assessment

First Posted Date: 2014-01-29

Last Posted Date: 2018-08-14

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 26

Registration Number: NCT02048020

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus

Phase 2

Completed

Conditions: Progesterone Receptor-positive Breast Cancer
Estrogen Receptor-positive Breast Cancer
Oral Complications
Stage IIIB Breast Cancer
HER2-negative Breast Cancer
Recurrent Breast Cancer
Stage IV Breast Cancer
Stage IIIC Breast Cancer

Interventions: Drug: mucoadhesive oral wound rinse
Other: laboratory biomarker analysis

First Posted Date: 2013-12-19

Last Posted Date: 2020-09-21

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 61

Registration Number: NCT02015559

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: degarelix
Drug: enzalutamide
Drug: trametinib
Drug: dasatinib

First Posted Date: 2013-11-21

Last Posted Date: 2024-10-01

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 45

Registration Number: NCT01990196

Locations: 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States

Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery

Phase 1

Completed

Conditions: Recurrent Prostate Cancer
Stage IIA Prostate Cancer
Stage IV Prostate Cancer
Adenocarcinoma of the Prostate
Stage IIB Prostate Cancer
Stage III Prostate Cancer
Stage I Prostate Cancer

Interventions: Dietary Supplement: green tea extract
Other: placebo
Drug: quercetin
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis

First Posted Date: 2013-07-31

Last Posted Date: 2021-06-23

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 32

Registration Number: NCT01912820

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Veterans Administration Los Angeles Healthcare System, Los Angeles, California, United States

Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective

Early Phase 1

Completed

Conditions: Neuroendocrine Tumors

Interventions: Drug: 68Ga-DOTATATE

First Posted Date: 2013-06-10

Last Posted Date: 2024-07-19

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 100

Registration Number: NCT01873248

Locations: 🇺🇸
University of California Los Angeles, Nuclear Medicine Clinic of the Department of Molecular and Medical Pharmacology, Los Angeles, California, United States

Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer

Phase 2

Withdrawn

Conditions: Adenocarcinoma of the Prostate
Stage I Prostate Cancer
Stage IIA Prostate Cancer
Recurrent Prostate Cancer
Stage IIB Prostate Cancer

Interventions: Radiation: brachytherapy
Radiation: image-guided radiation therapy
Other: laboratory biomarker analysis

First Posted Date: 2013-05-22

Last Posted Date: 2020-07-27

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT01859689

Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma

Phase 3

Withdrawn

Conditions: Stage IIC Melanoma
Stage IB Melanoma
Stage IIB Melanoma
Stage IIA Melanoma

Interventions: Procedure: sentinel lymph node biopsy
Biological: sargramostim
Other: laboratory biomarker analysis
Other: hypertonic saline

First Posted Date: 2013-04-09

Last Posted Date: 2020-07-27

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT01826864

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Home Terms & Conditions Privacy Policy